Description
Tesamorelin is a growth hormone releasing hormone (GHRH) analogue consisting of standard GHRH to which an additional trans-3-hexanoic acid group has been added. Produced by Theratechnologies of Canada, Tesamorelin became the newest drug to be approved by the FDA for use in HIV-associated lipodystrophy in 2010. The peptide has also been investigated for its ability to improve peripheral nerve regeneration and as a potential intervention for mild cognitive impairment (MCI), the precursor to dementia.
Product Usage
This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.
Benefits of Tesamorelin
- Increased Stability: Enhanced stability in human plasma extends the half-life of tesamorelin.
- Reduced Side Effects: Maintains physiological action of GHRH, resulting in fewer side effects.
- Effective Lipodystrophy Treatment: Reduces adiposity by nearly 20% in HIV-associated lipodystrophy patients.
- Improved Cardiovascular Health: Decreases triglyceride, total cholesterol, and non-HDL-C levels.
- Decreased Inflammation: Reduces ectopic fat deposition, lowering inflammation and CVD risk.
- Growth Hormone Deficiency Treatment: Safely raises GH levels, especially in HIV-positive individuals.
- Peripheral Nerve Damage Repair: Enhances healing of peripheral nerve injuries.
- Cognitive Function Enhancement: Improves cognition in early-stage dementia patients.
- Approved by FDA: Recognized for the treatment of HIV-associated lipodystrophy.
- Research-Backed Efficacy: Proven more effective than other available therapies for adiposity reduction.
Structure of Tesamorelin Peptide
Sequence: Unk-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu
Molecular Formula: C223H370N72O69S
Molecular Weight: 5195.908 g/mol
PubChem CID: 44147413
CAS Number: 901758-09-6
Research Findings on Tesamorelin
As a GHRH analogue, tesamorelin has similar effects to GHRH and other GHRH analogues like sermorelin, GRF (1-29), and CJC-1295. The addition of trans-3-hexanoic acid increases its stability in human plasma, extending its half-life. Despite this longer half-life, tesamorelin maintains the physiological action of GHRH, resulting in fewer side effects compared to molecules that disrupt normal pulsatile GH release.
Tesamorelin and Lipodystrophy
Tesamorelin is primarily used to treat HIV-associated lipodystrophy, a condition characterized by excessive fat accumulation in the abdomen and other body areas. This condition results from both HIV infection and antiretroviral therapy, particularly protease inhibitors. Initially, patients relied on diet, exercise, and a few ineffective medications for treatment. Surgery was a last-resort option with complications. In 2010, the FDA approved tesamorelin for treating HIV-associated lipodystrophy, reducing adiposity by nearly 20%. Research indicates tesamorelin is about four times more effective in reducing adiposity than all other available therapies combined.
Tesamorelin Investigated in Cardiac Disease
HIV-positive individuals have an increased risk of cardiovascular disease (CVD) due to abnormal fat deposition and the effects of antiretroviral drugs. Prevention of CVD is a critical medical intervention for their long-term well-being. Statins have been the primary medical management for this population. Tesamorelin has been shown to reduce triglyceride levels, total cholesterol levels, and non-HDL-C levels in HIV-positive patients. A 15% reduction in visceral adipose tissue with tesamorelin correlates with a 50 mg decrease in triglyceride levels. Reducing ectopic fat deposition decreases inflammation and the risk of CVD.
Changes in triglyceride levels of HIV-positive patients who respond to tesamorelin. Source: PubMed
Growth Hormone Deficiency and HIV
HAART is associated with endocrine and metabolic problems, including growth hormone (GH) deficiency. Approximately one-third of HIV patients on HAART have GH deficiency, which may contribute to the prevalence of lipodystrophy. Tesamorelin is a safer and more effective way to raise GH levels than exogenous GH administration, particularly for HIV-positive individuals.
Tesamorelin for Peripheral Nerve Damage
Peripheral nerve damage, resulting from injury, diabetes, or surgery, often causes debilitating motor and sensory function issues. Research suggests that growth hormone manipulation therapies, including tesamorelin, may improve peripheral nerve injury outcomes by increasing healing rates and extents.
Tesamorelin Investigated in Dementia
Evidence suggests that GHRH analogues like tesamorelin can enhance cognition in early-stage dementia patients. A study at the University of Washington School of Medicine found that tesamorelin may affect dementia by increasing gamma-aminobutyric acid (GABA) levels and decreasing myo-inositol (MI) levels in the brain. These findings indicate potential for using tesamorelin in dementia treatment and suggest new research avenues for prevention and cure.
Tesamorelin improves both executive function and verbal memory in patients suffering from mild cognitive impairment. Source: PubMed
Packaging
Single vial containing lyophilized product. Each vial contains 6mg Tesamorelin
FAQ
Tesamorelin is a synthetic peptide that acts as a growth hormone-releasing hormone (GHRH) analogue, enhancing growth hormone production and offering therapeutic benefits for various conditions.
Tesamorelin works by mimicking GHRH, stimulating the pituitary gland to release growth hormone, which in turn helps reduce fat deposits and improve overall metabolic health.
Benefits of Tesamorelin include increased stability in plasma, fewer side effects compared to other treatments, effective reduction of adiposity, improved cardiovascular health, decreased inflammation, and potential cognitive enhancements.
Disclaimer
This information is not intended to replace professional medical advice. Always consult with a healthcare professional before starting any new supplements.
